抗癌药们的研发，终于摁下加速键
人类从未停止过与癌症、阿尔兹海默症、艾滋病等疾病等抗争。但苦于新药研发的速度，这场疾病抗争史迟迟未能出现质的改变。而以生成式AI为基础的大模型的出现，正在从根本上改变这一进程。
C12.ai has announced the completion of a ¥50M funding round, alongside the release of its first production results from BeOne Medicines' pharmaceutical laboratory.
The company's Physical AI Scientist, named Talos, has been operating continuously for 50 days inside BeOne Medicines' real R&D environment. During this period, Talos successfully purified 15 real drug molecule intermediates with a 93% success rate, performing over 300 physical operations with zero execution errors.
What makes this achievement remarkable is that Talos operates in an unmodified lab environment — no special infrastructure or renovations were required. The robot works alongside human scientists, handling the repetitive physical tasks that traditionally consume over 50% of a researcher's time.
The system's performance has been benchmarked against experienced medicinal chemists, with Talos matching the output quality of scientists with over a decade of hands-on experience. This validation in a production-grade pharmaceutical setting marks a significant milestone for Physical AI in the life sciences industry.
Backed by YongHua Capital, Yunqi Partners, and WH Capital, C12.ai plans to expand its operations and bring Talos to additional pharmaceutical and molecular science laboratories.